Abciximab-induced thrombocytopenia: Correct management

Creative Commons License

Kelkitli E., Odabaşi Giden A., Denız Kürekçi D., Turgut M.

Journal of Experimental and Clinical Medicine (Turkey), vol.39, no.2, pp.581-583, 2022 (Scopus) identifier

  • Publication Type: Article / Article
  • Volume: 39 Issue: 2
  • Publication Date: 2022
  • Doi Number: 10.52142/omujecm.39.2.58
  • Journal Name: Journal of Experimental and Clinical Medicine (Turkey)
  • Journal Indexes: Scopus, Academic Search Premier, EMBASE
  • Page Numbers: pp.581-583
  • Keywords: Abciximab, glycoprotein IIb/IIIa receptor inhibitors, side effect, thrombocytopenia
  • Ondokuz Mayıs University Affiliated: Yes

Abstract

Thrombocytopenia is a possible side effect of routinely administered medical agents. Abciximab is one of the three potent intravenous glycoprotein IIb/IIIa receptor inhibitors (along with eptifibatide and tirofiban) that have shown significant positive outcomes when used in patients with intracoronary thrombus. The use of abciximab was associated with the risk of thrombocytopenia. This case reported the development of thrombocytopenia and treatment management after using abciximab.